featured
AACR 2021: Addition of Ipilimumab to Adjuvant Nivolumab Did Not Improve Outcomes in Late-Stage Melanoma
The result may relate to a shorter treatment duration of the nivolumab-ipilimumab combination therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: